SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Mula, M (2017) New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective. CNS Drugs, 31 (1). pp. 11-17. ISSN 1179-1934 https://doi.org/10.1007/s40263-016-0398-4
SGUL Authors: Mula, Marco

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (506kB) | Preview

Abstract

Benzodiazepines represent the first-line treatment for the acute management of epileptic seizures and status epilepticus. The emergency use of benzodiazepines must be timely, and because most seizures occur outside of the hospital environment, there is a significant need for delivery methods that are easy for nonclinical caregivers to use and administer quickly and safely. In addition, the ideal route of administration should be reliable in terms of absorption. Rectal diazepam is the only licensed formulation in the USA, whereas rectal diazepam and buccal midazolam are currently licensed in the EU. However, the sometimes unpredictable absorption with rectal and buccal administration means they are not ideal routes. Several alternative routes are currently being explored. This is a narrative review of data about delivery methods for benzodiazepines alternative to the intravenous and oral routes for the acute treatment of seizures. Unconventional delivery options such as direct delivery to the central nervous system or inhalers are reported. Data show that intranasal diazepam or midazolam and the intramuscular auto-injector for midazolam are as effective as rectal or intravenous diazepam. Head-to-head comparisons with buccal midazolam are urgently needed. In addition, the majority of trials focused on children and adolescents, and further trials in adults are warranted.

Item Type: Article
Additional Information: The final publication is available at Springer via http://dx.doi.org/10.1007/s40263-016-0398-4
Keywords: Psychiatry, 1115 Pharmacology And Pharmaceutical Sciences, 1109 Neurosciences
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: CNS Drugs
ISSN: 1179-1934
Language: eng
Dates:
DateEvent
January 2017Published
9 December 2016Published Online
Publisher License: Publisher's own licence
PubMed ID: 27943132
Web of Science ID: WOS:000394151300002
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108799
Publisher's version: https://doi.org/10.1007/s40263-016-0398-4

Actions (login required)

Edit Item Edit Item